Inozyme Pharma Inc (NASDAQ: INZY)’s stock price has increased by 1.18 compared to its previous closing price of 1.27. However, the company has seen a -4.81% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-21 that BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company’s Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
Is It Worth Investing in Inozyme Pharma Inc (NASDAQ: INZY) Right Now?
The stock has a 36-month beta value of 1.29. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INZY is 43.55M, and at present, short sellers hold a 8.40% of that float. On February 21, 2025, the average trading volume of INZY was 814.33K shares.
INZY’s Market Performance
The stock of Inozyme Pharma Inc (INZY) has seen a -4.81% decrease in the past week, with a -1.15% drop in the past month, and a -55.38% fall in the past quarter. The volatility ratio for the week is 6.29%, and the volatility levels for the past 30 days are at 8.74% for INZY. The simple moving average for the past 20 days is -7.44% for INZY’s stock, with a -68.16% simple moving average for the past 200 days.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Raymond James repeating the rating for INZY by listing it as a “Outperform.” The predicted price for INZY in the upcoming period, according to Raymond James is $26 based on the research report published on December 12, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see INZY reach a price target of $16. The rating they have provided for INZY stocks is “Buy” according to the report published on September 12th, 2024.
Jefferies gave a rating of “Buy” to INZY, setting the target price at $17 in the report published on August 13th of the previous year.
INZY Trading at -37.12% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.52% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 6.29%, as shares sank -2.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.00% lower at present.
During the last 5 trading sessions, INZY fell by -4.81%, which changed the moving average for the period of 200-days by -72.89% in comparison to the 20-day moving average, which settled at $1.3882. In addition, Inozyme Pharma Inc saw -53.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INZY starting from Treco Douglas A, who sale 7,523 shares at the price of $6.94 back on Apr 02 ’24. After this action, Treco Douglas A now owns 20,665 shares of Inozyme Pharma Inc, valued at $52,210 using the latest closing price.
Stock Fundamentals for INZY
Current profitability levels for the company are sitting at:
- -50.44 for the present operating margin
- 0.56 for the gross margin
The net margin for Inozyme Pharma Inc stands at -48.83. The total capital return value is set at -0.8. Equity return is now at value -79.42, with -55.29 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.95. The debt to equity ratio resting at 0.57. The interest coverage ratio of the stock is -13.34.
Currently, EBITDA for the company is -74.81 million with net debt to EBITDA at -0.25. When we switch over and look at the enterprise to sales, we see a ratio of 53.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.68.
Conclusion
To sum up, Inozyme Pharma Inc (INZY) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
